Skip to content
Screener

Entrada Therapeutics TRDA Q1 2026 earnings

Reported May 7, 2026 · Before market open

Revenue$875.0KMiss by $2.0M
EPS-$0.95Beat by $0.11
Revenue estimate$2.9M
EPS estimate-$1.06

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$2.1M
EPS estimate-$0.98

FAQ

When did Entrada Therapeutics report Q1 2026 earnings?
Entrada Therapeutics (TRDA) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Entrada Therapeutics's Q1 2026 revenue and EPS?
Entrada Therapeutics reported revenue of $875.0K and eps of $-0.95 for Q1 2026.
Did Entrada Therapeutics beat estimates in Q1 2026?
Revenue missed the consensus estimate of $2.9M by $2.0M. EPS beat the consensus estimate of $-1.06 by $0.11.
How did Entrada Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 95.7% from $20.6M a year earlier and eps declined 126.2% from $-0.42.
Where can I find Entrada Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001689375-26-000027) and the 10-Q periodic report (0001689375-26-000028) directly on SEC EDGAR. The filing index links above go to sec.gov.